Literature DB >> 34653429

The molecular mechanisms and therapeutic potential of EZH2 in breast cancer.

Sara Adibfar1, Marischa Elveny2, Hadisha Sh Kashikova3, Maria Vladimirovna Mikhailova4, Pooya Farhangnia5, Sajjad Vakili-Samiani6, Hanieh Tarokhian7, Farhad Jadidi-Niaragh8.   

Abstract

Due to its high occurrence and mortality rate, breast cancer has been studied from various aspects as one of the cancer field's hot topics in the last decade. Epigenetic alterations are spoused to be highly effective in breast cancer development. Enhancer of zeste homolog 2 (EZH2) is an enzymatic epi-protein that takes part in most vital cell functions by its different action modes. EZH2 is suggested to be dysregulated in specific breast cancer types, particularly in advanced stages. Mounting evidence revealed that EZH2 overexpression or dysfunction affects the pathophysiology of breast cancer. In this review, we discuss biological aspects of the EZH2 molecule with a focus on its newly identified action mechanisms. We also highlight how EZH2 plays an essential role in breast cancer initiation, progression, metastasis, and invasion, which emerged as a worthy target for treating breast cancer in different approaches.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Breast cancer; EZH2; Targeted-therapy

Mesh:

Substances:

Year:  2021        PMID: 34653429     DOI: 10.1016/j.lfs.2021.120047

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

Review 1.  Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.

Authors:  Hikaru Nanamori; Yu Sawada
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

2.  Integrative Bioinformatics Analysis Reveals CHEK1 and UBE2C as Luminal A Breast Cancer Subtype Biomarkers.

Authors:  Daowu Yu; Shengwei Liu; Yijun Chen; Lumeng Yang
Journal:  Front Genet       Date:  2022-07-12       Impact factor: 4.772

3.  SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.

Authors:  Tian Tian; Jiwei Li; Di Shi; Yupeng Zeng; Baohua Yu; Xiaoqiu Li; Ping Wei; Xiaoyan Zhou
Journal:  Cell Death Dis       Date:  2022-09-03       Impact factor: 9.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.